Non-small cell lung cancer (NSCLC) consists of several histomorphologically defined
phenotypes that display an enormous genetic variability. In recent years, epidermal growth …

Tobacco use after cancer diagnosis is associated with adverse cancer outcomes, yet
reliable prevalence estimates for this behavior are lacking. We conducted a systematic …

Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

BACKGROUND: The overall incidence and risk of nail changes associated with the use of
epidermal growth factor receptor inhibitors (EGFRIs) varies widely across the literature …

Background Many targeted therapies used in the treatment of cancer can lead to the
development of xerosis, but the incidence and relative risk of xerosis have not been …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …

Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths. In
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …

Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …

Introduction Lung cancer is a significant burden on societies worldwide, and the most
common cause of death in patients with cancer overall. Exercise intervention studies in …